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Systemic mastocytosis is a rare disease and characterized by excessive mast cell accumulation in one or
multiple organs. One subtype of systemic mastocytosis is systemic mastocytosis-associated clonal he-
matological non-mast cell lineage disease (SM-AHMND), which indicates concurrent evolution of two
separate clonal entities, one consisting of mast cells and one as a second hematological as well as non-
mast cell origin disease. When SM-AHMND is diagnosed, bone marrow examination is essential for the
initial approach, because marrow is almost universally involved in adult mastocytosis and it facilitates
detection of a second hematological neoplasm. Myeloid neoplasm is reported to be the most prevalent
associated clonal hematological non-mast cell disease. Treatment strategy and outcome for SM-AHMND
is dependent on hematological non-mast cell lineage disease. Herein, we have presented a case report of
diffuse large B cell lymphoma coexisting with systemic mastocytosis where the patient underwent
successful chemotherapy leading to extended survival duration.
Copyright © 2016, The Chinese Oncology Society. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Mastocytosis indicates a group of disorders characterized by
excessive mast cell accumulation in one or multiple organs and is a
type of myeloproliferative neoplasm disorder, according to the
2008 World Health Organization (WHO) classiﬁcation of tumors of
hematopoietic and lymphoid tissues Non-Hodgkin lymphoma.1
Mastocytosis is heterogeneous and can involve multiple sites,
ranging from skin lesions, which may spontaneously resolve to
highly aggressive mast cell leukemia associated with multiple or-
gan failure. It is a rare disease and its exact incidence is unknown.
Subtypes of mastocytosis are recognized primarily through clinicalional Yang-Ming University,
ncology Society.
Society. Production and hosting bypresentation and distribution of disease. Mast cell inﬁltration
conﬁned to the skin is cutaneous mastocytosis, whereas systemic
mastocytosis (SM) is regarded as involvement of at least one extra-
cutaneous organ with or without the presence of skin lesions.2
Clinically, SM is classiﬁed as indolent SM (ISM), aggressive SM
(ASA), SM with associated clonal hematological non-mast cell
lineage disease (SM-AHMND), and mast cell leukemia (MCL).1 ISM,
themost common subgroup among SM, usually refers to symptoms
resulting from mast cell degranulation, mediator release, allergies
or anaphylaxis and no evidence of extra-cutaneous organ
dysfunction or failure,3 while ASM indicates the presence of extra-
cutaneous organ dysfunction or failure caused by mast cell inﬁl-
tration.4 On the other hand, SM-AHNMD is the second most com-
mon SM subgroup and myeloid neoplasm is reported most
frequently as hematological non-mast cell lineage disease.3 Bone
marrow (BM) examination is suggested as part of the initial diag-
nostic work-up for SM, because BM is almost universally involved
in adult mastocytosis. Furthermore, BM examination also allows forElsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
Fig. 2. CD-20 immuno-histochemical stain demonstration on diffuse large B cell
lymphoma.
Fig. 3. Mast cell aggregation and inﬁltration, these cells were oval to spindle-shaped
and containing moderate amount of pale cytoplasm.
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uncommon disease, SM coexistent with lymphoid neoplasm is
extremely rare. Here, we present an interesting case of SM coex-
istent with diffuse large B cell lymphoma (DLBCL).
2. Case report
A 51-years-old man visited our hospital presenting with a
palpablemass over the right inguinal areawhich had persisted for 3
months. This lesion was approximately 3e4 cm, ﬁrm and had
progressively enlarged. Laboratory data showed no remarkable
anomaly except elevated lactate dehydrogenase (265 U/L). The
patient denied experiencing any signiﬁcant weight loss, poor
appetite, night sweats, or sustained fever. After discussing his cir-
cumstances with the hematologist in our outpatient department,
the patient agreed to undergo surgical excision biopsy. Subsequent
histological analysis revealed DLBCL and he underwent further
computed tomography with contrast, and BM examination for
complete staging. The computed tomography showed right lumbar,
iliac and right inguinal lymphoadenopathies, and his clinical Ann
Arbor staging was designated as stage II. Further BM examination
disclosed diffuse proliferation of large atypical CD20-positive
lymphoid cells using hematoxylin and eosin staining (Fig. 1) and
immune-histochemical stain (Fig. 2). This is compatible with
diffuse large B cell lymphoma, and the patient's staging was
upgraded to stage IV. However, at the low power ﬁeld of 40X,
multiple well-circumscribed aggregates of polygonal cells with pale
cytoplasm were observed in the bone marrow. At the high power
ﬁeld designation of 200X, these cells were oval to spindle-shaped
and contained a moderate amount of pale cytoplasm (Fig. 3),
which showed positive for tryptase (Fig. 4) and CD25 (Fig. 5)
through immune-histochemical evaluation. The picture was
compatible with systemic mastocytosis with associated clonal he-
matological non-mast cell lineage disease. Thus, the ﬁnal diagnosis
for this male patient was DLBCL, with right lumbar, iliac and right
inguinal lymphoadenopathies and BM involvement, Ann Arbor
stage IVA, International Prognostic Index 3, coexisting with SM. In
March 2013 he began a course of immune chemotherapy with
rituximab, cyclophosphamide, vincristine and prednisolone
(ReCHOP), which was the standard treatment for DLBCL. The
treatment consisting of 6 courses of ReCHOP was completed in
September 2013, and a follow-up integrated Positron emission to-
mography and computerized tomography (PET-CT) scan revealedFig. 1. Diffuse large B cell lymphoma with bone marrow involvement in hematoxylin
and eosin stain.
Fig. 4. Tryptase stain demonstration on mast cell.nearly complete remission of DLBCL. The port-A was removed in
April 2015, as scheduled, and the patient was followed-up regularly
in the outpatient department presenting in routine stable
condition.
Fig. 5. CD-25 immuno-histochemical stain demonstration on mast cell.
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Although mastocytosis is a rare disease, it may occur in any age
and its presentation is can vary with age. Cutaneous mastocytosis is
most common in children, while SM is usually diagnosed in pa-
tients > 20 years of age.5 According to the WHO classiﬁcation, the
major criterion for SM diagnosis is that multifocal, dense inﬁltrates
of mast cells (15 mast cells in aggregates) are detected in sections
of bone marrow and/or other extra-cutaneous organs. The other
minor criteria for diagnosis are based on either mast cell
morphology, genetic mutation at codon 816 of KIT, detection of
surface markers of CD2 and/or CD25 or serum total tryptase. Suc-
cessfully documented diagnosis for SM needs to meet the major
criterion and one of minor criteria, or three of minor criteria
(Table 1). Recent study revealed mastocytosis was associated with
somatic gain-of-function point mutationwithin KIT tyrosine kinase
domain, particularly the D816V mutation6,7 and it has been regard
as minor criterion for diagnosis, irrespective of WHO SM subtype.
Another important approach tool is tryptase, which can be detected
in both mast cell or serum, and elevated serum tryptase
level > 20 ng/ml; however, this is also regarded as a minor criterion
for SM diagnosis in WHO framework. One earlier study disclosed
that ASM and SM-AHNMD patients exhibited a higher level of
serum tryptase (usually > 200 ng/ml) than thosewith ISM.3 Of note,
serum tryptase levels are also elevated in certain hematological
diseases, such as acute myeloid leukemia, chronic myeloid leuke-
mia and myelodysplastic syndrome.8 BM examination is undoubt-
edly most essential for the study of both SM and lymphoma for
staging, because BM is almost universally involved in adult mas-
tocytosis. Berezowska et al had reviewed 59 adults with initial
presentation of skin mastocytosis and 57 (96%) of whom were
eventually diagnosed with SM by further bone marrow examina-
tion. In that study, 42 (71%) subjects met the major criterion andTable 1
Criteria for systemic mastocytosis diagnosis by World Health Organization.a
Major
Multifocal, dense aggregates of mast cells (15 or more) detected in sections of bone m
Minor
1. In biopsy section, more than 25% of the masts cells in the inﬁltrate have atypical morp
or atypical
2. Mast cells co-express CD117 with CD2 and/or CD25
3. Detection of KIT point mutation at codon 816 in bone marrow, blood, or other extra
4. Serum total tryptase persistently > 20 ng/ml (not a valid criteria in cases of systemi
a Diagnosis may be rendered if one major plus one minor or three minor criteria are fone minor criterion, while the other 15 (25%) met three of the
minor criteria.9In addition, BM examination also allows for detec-
tion of a second hematological neoplasm. In this case presentation,
diagnosis of SM was obtained from BM examination for DLBCL
staging and involving SM-AHMND.
Chronicmyelomonocytic leukemia has been reported as themost
prevalent concomitant hematological neoplasm, followed by mye-
lodysplastic, myeloproliferative syndrome, and acute myeloid leu-
kemia10; on the other hand, Lymphoproliferative neoplasms were
less frequency associated with SM-AHMND.7 In another retrospec-
tive study of 342 consecutive patients with SM at the Mayo Clinic
extending from 1976 to 2007, their investigation demonstrated that
the proportion of SM in ISM, SM-AHMND, ASM, and mast cell leu-
kemia is 46%, 40%,12% and 1%, respectively.3 Regarding SM-AHMND,
123 (89%) were associated with myeloid neoplasm, while the
remainder were lymphoma (n ¼ 7), myeloma (n ¼ 5), chronic lym-
phocytic leukemia (n ¼ 2), or primary amyloidosis (n ¼ 1). The sub-
classiﬁcation of SM-AHMND associated with myeloid neoplasmwas
as follows: 55 (45%) myeloproliferative neoplasm, 36 (29%) chronic
myelomonocytic leukemia, 28 (23%) myelodysplastic syndrome and
4 (3%) acute leukemia. Although lymphoid neoplasms were less
frequently associated with SM-AHMND, in the case of lymphoid
malignancies, almost all B cell neoplasms may develop currently
with SM.10 This phenomenon may be attributed to interactions be-
tween the B cell neoplasms and mast cells. One study based on pa-
tient pathological ﬁndings suggested that angiogenesis andmast cell
density with tryptase activity would increase simultaneously path-
ological progression in B cell non-Hodgkin's lymphomas.11 For ISM
treatment, managing histamine symptoms such as anaphylaxis,
pruritus, malabsorption, and ﬂashing could be achieved by
interferon-alpha, corticosteroids, and cytoreductive therapies, such
as cladribine.4 The small-molecule kinase inhibitors, such as imati-
nib, have yielded only modest clinical beneﬁt, because of unrecog-
nized complexities in their molecular pathogenesis.12,13 The survival
duration of ISM was not signiﬁcantly different from the normal
population.14 On the other hand, treatment and outcome for SM-
AHMND is dependent on hematological non-mast cell lineage dis-
ease. The clinical course and prognosis are strongly correlated with
hematological non-mast cell lineage, and the standard regimen for
this non-mast cell disease should be administration together with
SM management.4 An earlier study reported the overall median
survival rate for patients with SM-AHMND was 24 months, but this
survival time varied by subgroup. For example, SM-
myeloproliferative neoplasm patients had a signiﬁcant longer sur-
vival time (31 months) than thosewith SM-chronic myelomonocytic
leukemia (15months), thosewith SM-myelodysplastic syndrome (13
months), and those with SM-acute leukemia (11 months).15,16 Lim
et al identiﬁed weight loss, advanced age, thrombocytopenia, ane-
mia, hypoalbuminemia, and excess BM blast as adverse prognostic
factors for SM.3 Schipper et al reported a 74-year-old male patient
with SM coexisting with DLBCL, and the survival time of this patient
was merely seven months owing to lymphoma progression despite
immune-chemotherapy administration.17 In our case, the patientarrow and conﬁrmed by tryptase immunohistochemistry or other special stains
hology, or, of all the mast cells in the aspirate smear, more than 25% are immature
-cutaneous organs
c mastocytosis with associated clonal hematologic non-mast cell lineage disease)
ulﬁlled.
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experienced long-term survival time.
In conclusion, mastocytosis refers to a group of disorders char-
acterized by excessive mast cell accumulation in one or multiple
organs, while SM-AHMND is a distinct form of SM characterized by
concurrent evolution of two separate clonal entities. BM exami-
nation is essential for initial approach which allows for the possi-
bility of detecting both hematological non-mast cell as well as
lymphoma staging. Proper course of treatment is guided by the
standard regimen for hematological non-mast cell disease. Careful
and comprehensive work-up for tumor study or staging is usually
the key to disclose coexistent rare disease, and detailed and precise
diagnosis may improve patient's outcome.
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